Analysis of the utilization patterns and costs of BTK inhibitors in B-cell lymphoma
10.13699/j.cnki.1001-6821.2024.10.027
- VernacularTitle:BTK抑制药在B细胞淋巴瘤中的用药模式与治疗费用分析
- Author:
Dan JIANG
1
;
Zai-Wei SONG
;
Yang HU
;
Fei DONG
;
Rong-Sheng ZHAO
Author Information
1. 北京大学第三医院药学部,北京 100191;北京大学医学部药物评价中心,北京 100191;北京大学医学部药学院药事管理与临床药学系,北京 100191
- Keywords:
ibrutinib;
zanubrutinib;
Bruton's tyrosine kinase inhibitor;
utilization pattern;
cost;
treatment interruption
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(10):1520-1524
- CountryChina
- Language:Chinese
-
Abstract:
Objective To elucidate utilization patterns,cost and safety of Bruton's tyrosine kinase inhibitors(BTKi)in the real world.Methods A retrospective cohort was designed and constructed using real-world BTKi data from a single lymphoma center.Descriptive analysis was performed to describe the demographic and clinical characteristics of the population.Medicine utilization and cost were quantified by defined daily doses(DDDs)and defined daily dose cost(DDDc),respectively.A generalized estimating equation(GEE)was used to explore the potential influencing factors of platelet aggregation rate(PAR).Results The study cohort included 193 patients[median age,65 years;77(39.90％)women],most of whom received ibrutinib(n=109,56.48％),and 77.20％patients combined BTKi with chemotherapy or targeted therapy.The implementation of national negotiation policy had a large impact on medicine utilization and cost.The DDDs difference between the two BTKis was reduced from 18.55 to 1.41 times.The DDDc for ibrutinib decreased from 1 619.99 Yuan to 567.00 Yuan,and that for zanubrutinib from 706.25 Yuan to 340.00 Yuan was already lower than ibrutinib.Interruptions were more readily observed in patients treated with ibrutinib,and hematological toxicity was the main adverse drug event(ADE)leading to treatment interruption.Besides,the GEE model showed that combining BTKi with antiplatelet medication significantly decreases the PAR[β=-34.35％,95％confidence interval(CI):-41.60％--27.11％,P＜0.001].Compared to zanubrutinib,ibrutinib also notably reduces the PAR(β=-12.38％,95％CI:-24.50％--0.27％,P＜0.05).Conclusion After the implementation of national negotiation policy,there is no significant difference in the clinical preference for two BTKis.Compared with ibrutinib,zanubrutinib showed an advantage in terms of economic profile,treatment interruptions caused by ADE,and the effect on PAR.
